Why is PTEN an important tumor suppressor?

Journal of Cellular Biochemistry

Volumn 102, Issue 6, 2007, Pages 1368-1374

  Li, Li ^a   Ross, Alonzo H ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Department of Biochemistry and Molecular Pharmacology ^*  (United States)

Author keywords

Chromosomal aberrations; p53; Phosphatase; Phosphatidylinositol; Tumor suppressor

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

ANGIOGENESIS; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOME 10; DISEASE COURSE; GENOMIC INSTABILITY; HUMAN; MULTIPLE CANCER; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

FORECASTING; HUMANS; MODELS, BIOLOGICAL; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 36849018402     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21593     Document Type: Review

References (46)

1. Bjornsti MA, Houghton PJ. 2004. The tor pathway: A target for cancer therapy. Nat Rev Cancer 4:335-348.
2. Bolton PF, Griffiths PD. 1997. Association of tuberous sclerosis of temporal lobes with autism and atypical autism. Lancet 349:392-395.
3. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. 2004. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64:5048-5050.
4. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, Eng C. 2005. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42:318-321.
5. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE. 2007. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444.
6. Chan S. 2004. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer 91:1420-1424.
7. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-730.
8. +/- mice. Genes Dev 20:1569-1574.
9. Collado M, Blasco MA, Serrano M. 2007. Cellular senescence in cancer and aging. Cell 130:223-233.
10. Cully M, You H, Levine AJ, Mak TW. 2006. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192.
11. Curatolo P, Porfirio MC, Manzi B, Seri S. 2004. Autism in tuberous sclerosis. Eur J Paediatr Neurol 8:327-332.
12. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H. 2003. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3:117-130.
13. Georgescu M-M, Kirsch KH, Akagi T, Shishido T, Hanafusa H. 1999. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A 96:10182-10187.
14. Gericke A, Munson M, Ross AH. 2006. Regulation of the PTEN phosphatase. Gene 374:1-9.
15. Gual P, Le Marchand-Brustel Y, Tanti JF. 2005. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:99-109.
16. Hawkins PT, Anderson KE, Davidson K, Stephens LR. 2006. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 34:647-662.
17. Iijima M, Devreotes P. 2002. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell 109:599-610.
18. 2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3:513-519.
19. Krystal G. 2000. Lipid phosphatases in the immune system. Seminars Immunol 12:397-403.
20. Lazar DF, Saltiel AR. 2006. Lipid phosphatases as drug discovery targets for type 2 diabetes. Nat Rev Drug Discov 5:333-342.
21. Lee YH, Giraud J, Davis RJ, White MF. 2003. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 278:2896-2902.
22. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
23. Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67.
24. Luo J, Manning BD, Cantley LC. 2003. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 4:257-262.
25. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J Biol Chem 273:13375-13378.
26. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. 2005. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19:1773-1778.
27. Mayo LD, Donner DB. 2001. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98:11598-11603.
28. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. 2002. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484-5489.
29. Oda K, Stokoe D, Taketani Y, McCormick F. 2005. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669-10673.
30. Pagliarini DJ, Worby CA, Dixon JE. 2004. A PTEN-like phosphatase with a novel substrate specificity. J Biol Chem 279:38590-38596.
31. Puc J, Parsons R. 2005. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 4:927-929.
32. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty W, Gaciong Z, Meek SE, Piwnica-Worms H, Hibshoosh H, Parsons R. 2005. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7:193-204.
33. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. 2005. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554-2559.
34. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
35. Sansal I, Sellers WR. 2004. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22:2954-2963.
36. Sharrard RM, Maitland NJ. 2007. Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines. Cell Signal 19:129-138.
37. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. 2007. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128:157-170.
38. Simpson L, Parsons R. 2001. PTEN: Life as a tumor suppressor. Exp Cell Res 264:29-41.
39. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. 2001. Regulation of PTEN Transcription by p53. Mol Cell 8:317-325.
40. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 15:356-362.
41. Stocker H, Andjelkovic M, Oldham S, Laffargue M, Wymann MP, Hemmings BA, Hafen E. 2002. Living with lethal PIP3 levels: Viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 295:2088-2091.
42. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501.
43. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. 2007. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11:555-569.
44. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. 2007. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32:342-349.
45. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X. 2007. NEDD 4-lis a protooncogenic ubiquitin ligase for PTEN. Cell 128:129-139.
46. Zhou M, Gu L, Findley HW, Jiang R, Woods WG. 2003. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 63:6357-6362.